In the FOURIER trial, the hazard ratio (HR) for venous thromboembolism with evolocumab was 0.71 (95% CI: 0.50–1.00), while in the ODYSSEY trial, the HR was 0.67 (95% CI: 0.44–1.01). A meta-analysis of the two trials demonstrated a statistically significant 31% relative risk reduction in VTE with PCSK9 inhibition compared with placebo (HR 0.69; 95% CI: 0.53–0.90). This evidence concerns the gene PCSK9 and venous thromboembolism.